Vitamin B3 supplement studied for rare lung condition
NCT ID NCT07563322
First seen May 13, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This study tests whether nicotinamide riboside, a form of vitamin B3, can improve how cells produce energy in people with combined pulmonary hypertension (CPH). CPH is a serious lung and heart condition with no approved treatments. Ten participants will receive both the supplement and a placebo at different times to see how it affects biological markers in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY HYPERTENSION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37203, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nicotinamide riboside (a form of vitamin B3)
What this could lead to
If it works, this could point toward a new way to support cell energy in people with combined pulmonary hypertension, but it is not a treatment test.
What could go wrong
This is a very small, early study with only 10 people. It looks at biological markers, not symptoms or survival, so even positive results may not lead to a real treatment.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.